May 29, 2026
The biotechnology and pharmaceutical sector continues to advance through a combination of large-scale strategic investment, rapid progress in advanced therapeutic modalities, and mounting pressure to demonstrate durable clinical and commercial outcomes. Growth remains particularly strong across cell therapy, metabolic disease, neuroscience, gene therapy, and infectious disease, while artificial intelligence and industrial-scale manufacturing capabilities are becoming increasingly central to how organisations are positioning for long-term competitiveness.
Capital deployment, partnering activity, and public market financings continue to reshape competitive dynamics, but this momentum is increasingly accompanied by more scrutiny around clinical value, regulatory standards, healthcare system capacity, and patient access. The result is an industry that remains highly active, yet progressively more selective in how innovation is funded, developed, and scaled.
Strategic Expansion, Platform Technologies and Competitive Positioning
Deal activity this period continued to cluster around platform expansion and capability acquisition, particularly in areas where companies are seeking durable differentiation rather than incremental pipeline additions.
A notable example came from Eli Lilly, which committed up to $7B to acquire Kelonia Therapeutics, securing access to an in vivo CAR-T platform targeting multiple myeloma. The approach reflects a broader shift in cell therapy strategy, where development is gradually moving away from complex ex vivo manufacturing toward in vivo engineering models that could ultimately simplify production and broaden accessibility. The transaction also reinforces the continued strategic importance of oncology as companies compete to establish leadership in next-generation immune-based therapies.
Neuroscience-related dealmaking also remained active, with UCB agreeing to acquire Neurona Therapeutics in a deal valued at up to $1.15B. The acquisition brings NRTX-1001, currently in early clinical development for drug-resistant mesial temporal lobe epilepsy, into UCB’s pipeline. The move highlights increasing willingness to invest earlier in neurological programmes as advances in cellular therapy and disease understanding begin to open historically challenging areas of CNS drug development.
In parallel, Biogen expanded its international footprint through a licensing arrangement granting Greater China rights to felzartamab from TJ Biopharma, in a transaction valued at up to $850M. The agreement extends access into immune-mediated kidney disease and multiple myeloma indications, illustrating how regional licensing continues to serve as a key mechanism for global expansion without requiring full commercial infrastructure deployment.
Industrial integration within generics and biosimilars also progressed, with Amneal Pharmaceuticals moving to acquire Kashiv BioSciences in a deal worth up to $1.1B. The combination strengthens end-to-end biosimilar development and manufacturing capacity, reflecting ongoing consolidation trends as companies seek scale efficiencies in increasingly competitive biologics markets.
Oncology-related expansion was not limited to therapeutics. Olympus expanded its presence in cancer care through a $270M transaction for Bioprotect, reinforcing a broader industry trend toward integrated oncology ecosystems. Rather than focusing solely on drug development, companies are increasingly investing across diagnostics, procedural technologies, and supportive care infrastructure to improve end-to-end treatment pathways and operational efficiency.
Therapeutic Innovation, Clinical Signals and Scientific Progress
Clinical development activity this period reflected both continued scientific progress and growing debate around how therapeutic success should be defined across different disease areas.
In autoimmune disease, Kyverna Therapeutics reported encouraging Phase 2 results for its CAR-T candidate miv-cel in stiff person syndrome. The programme is increasingly viewed as a potential first-in-class CAR-T therapy for an autoimmune indication, signalling how immune-cell engineering approaches are expanding beyond oncology into chronic and systemic inflammatory disease settings.
Gene therapy also advanced across multiple fronts. Regeneron secured FDA approval for Otarmeni in a rare inherited hearing loss indication, marking the first therapy cleared under the agency’s national priority voucher framework. At the same time, Ray Therapeutics raised $125M in an oversubscribed Series B round to progress retinal gene therapy programmes, underscoring sustained investor interest in ophthalmic genetic medicine despite technical and manufacturing complexity.
Neuroscience development activity remained broad, with Tortugas Neuroscience launching with $106M in capital alongside four Phase 2 assets licensed from Eisai and Hansoh. The formation reflects continued rebuilding of central nervous system pipelines through external innovation rather than purely internal discovery efforts.
However, Alzheimer’s disease once again became a focal point for debate following a review of 17 clinical studies assessing anti-amyloid therapies. While plaque reduction was consistently observed, the analysis found limited evidence of meaningful clinical improvement, alongside increased risk of adverse neurological effects such as brain swelling. The findings add further complexity to ongoing discussions around biomarker-driven approval pathways versus real-world therapeutic benefit in neurodegenerative disease.
In dermatology, Nektar Therapeutics reported sustained long-term improvement in patients treated with its alopecia programme, with early responders continuing to show progressive gains over extended follow-up. Durability of effect remains a key differentiator in chronic inflammatory and dermatological conditions, where long-term consistency often determines commercial viability.
In infectious disease, hepatitis B research produced encouraging mid-stage signals as GSK reported that approximately one-fifth of treated patients achieved functional cure outcomes with its investigational therapy. Given the long-standing difficulty of eradicating hepatitis B infection, these results represent incremental but meaningful progress toward more durable disease control strategies, particularly as companies explore combination and next-generation antiviral approaches aimed at functional cure rather than suppression alone.
Capital Markets, AI Infrastructure and Financing Innovation
Financing activity remained robust, particularly for companies operating in large addressable markets or advancing differentiated platform technologies with long-term scalability.
Kailera Therapeutics completed a $625M IPO to fund late-stage obesity programmes licensed from Hengrui, marking one of the largest recent biotechnology listings. The company is targeting major clinical readouts in the 2027–2028 timeframe, reflecting continued investor appetite for metabolic disease assets with large commercial potential and long development horizons.
In precision biology, Alamar Biosciences reached a valuation of approximately $1.5B following its Nasdaq debut, highlighting growing demand for proteomics platforms that support biomarker discovery and translational research. The result reinforces increasing convergence between diagnostics, data infrastructure, and therapeutic development.
Specialist venture capital activity also remained active, with Kurma Partners closing its Biofund IV at €215M, an increase from its prior fund. The vehicle continues to focus on early-stage companies developing therapies for severe and high-unmet-need conditions, reinforcing the importance of domain-specific capital in advancing complex scientific programmes.
Alternative financing structures also gained further traction. Apogee secured up to $1.3B in royalty-based funding to support Phase 3 development of its eczema programme. Such structures are increasingly used to reduce equity dilution while securing large-scale development capital, particularly in competitive inflammatory disease markets where clinical differentiation and commercial durability are critical.
Artificial intelligence infrastructure continued to deepen its integration into pharmaceutical operations. Merck entered a multiyear agreement with Google Cloud valued at up to $1B to deploy agentic AI systems across research, operational, and commercial functions. The scale of the partnership reflects the growing role of AI not as a support tool, but as a structural layer embedded across drug discovery and enterprise decision-making processes.
Public Health, Regulation and System-Level Dynamics
Regulatory developments and broader healthcare system pressures continued to influence both market expectations and strategic planning across the sector.
In Europe, approval was granted for Moderna’s mCombriax, a combined influenza and COVID-19 vaccine. Combination vaccination approaches are increasingly being adopted to streamline immunisation pathways, improve uptake, and reduce logistical burden on healthcare systems, particularly in seasonal respiratory disease management.
Public trust and communication around healthcare evidence remained under scrutiny following reports that a reviewed analysis suggesting COVID-19 vaccines significantly reduced hospitalisation rates was not published by the CDC. The situation has renewed discussion around transparency in public health communication and the intersection between scientific evidence, policy interpretation, and public confidence.
Policy influence also played a visible role in emerging therapeutic categories, with psychedelic biotech companies experiencing strong market reactions following reports that regulatory agencies were directed to accelerate review pathways for psychedelic therapies, including priority voucher mechanisms designed to shorten approval timelines for breakthrough-designated treatments.
Manufacturing capacity expansion remained another key theme. AbbVie selected North Carolina for a $1.4B injectable manufacturing campus focused on products such as vials and prefilled syringes. The investment reflects ongoing prioritisation of supply chain resilience and domestic production capacity as demand for injectable biologics continues to expand globally.
At the frontier of genomic science, researchers in Boston demonstrated the selective inactivation of an extra chromosome in Down syndrome cell models using CRISPR combined with XIST-mediated silencing. The approach achieved measurable silencing effects without disrupting healthy chromosome copies, representing an early-stage but notable step in chromosome-level gene regulation research.
Life Science Unlocked Takeaway
The biotechnology and pharmaceutical sector is continuing its transition toward a model defined by platform scalability, increasingly complex biologics, and deeper integration between computational systems and life science research.
While large-scale acquisitions, public market activity, and sustained investment in metabolic disease, neuroscience, and gene therapy signal continued confidence in long-term growth, the environment is becoming more selective in how progress is measured and rewarded.
At the same time, questions around clinical validity, regulatory standards, healthcare infrastructure, and system resilience are becoming more central to strategic decision-making.
Looking forward, competitive advantage is likely to depend not only on scientific innovation but on the ability to integrate technologies at scale, deploy capital efficiently, and operate effectively within an increasingly interconnected global healthcare ecosystem.
Contact Us!
✉️ Robert Green – +44 (0) 207 863 7302 (ext 802)
✉️ Daniel Bishop – +44 (0) 207 863 7302 (ext 804)
🌐 Explore more about us on our Website – www.greenlsr.com